PMID- 35130209
OWN - NLM
STAT- MEDLINE
DCOM- 20220209
LR  - 20221207
IS  - 0030-9982 (Print)
IS  - 0030-9982 (Linking)
VI  - 71(Suppl 8)
IP  - 12
DP  - 2021 Dec
TI  - Osteocalcin serum levels in obese patients with type 2 diabetes mellitus: The 
      virtual points observed in a case control study.
PG  - S4-S10
AB  - OBJECTIVE: To elucidate the effect of metformin alone or in combination with 
      sitagliptin on osteocalcin serum levels in obese patients with type 2 diabetes 
      mellitus (T2DM). METHODS: This case-control study was conducted at the Department 
      of Clinical Pharmacology and Therapeutic, College of Medicine, Mustansiriyah 
      University, Baghdad, Iraq, from February to April, 2019. This study comprised 62 
      obese T2DM patients compared with 28 healthy controls, they were divided into 
      three groups; Group I: Obese patients with T2DM on metformin (n=36), Group II: 
      Obese patients with T2DM on metformin plus sitagliptin (n=26), and Group III: 
      healthy controls subjects (n=28). Body mass index (BMI), blood pressure profile, 
      lipid profile, Glycaemic indices, and serum levels of human osteocalcin were 
      measured. The data analysis was done by using SPSS 20. RESULTS: Osteocalcin serum 
      level was lower in patients with T2DM compared with the control (P=0.001), also 
      it was relatively low in metformin (MT) group (21.04+/-3.16 ng/mL) compared to 
      sitagliptin (ST) group (25.65+/-7.30 ng/mL), (P=0.04). In relation to the HbA1c, 
      osteocalcin serum level was reduced in patients with T2DM with high HbA1c 
      (HbA1c-H) compared to the patients with T2DM with low HbA1c (HbA1c-L), (P=0.03) 
      and was not significantly different when compared with moderate HbA1c (HbA1c-M), 
      (P>0.05). However, osteocalcin was negatively correlated with HOMA-IR(r=-0.78, 
      P=0.0001). CONCLUSIONS: Osteocalcin serum level was reduced in T2DM patients and 
      negatively correlated with HOMA-IR and HbA1c and FBG. Combination of metformin 
      with sitagliptin was more effective than metformin monotherapy in amelioration of 
      osteocalcin serum level in patients with T2DM.
FAU - Shams, Hala Akeel
AU  - Shams HA
AD  - Department of Clinical Pharmacology, Medicine and Therapeutic, College of 
      Medicine, Al-Mustansiriya University, Baghdad, Iraq.
FAU - Al-Kuraishy, Hayder Mutter
AU  - Al-Kuraishy HM
AD  - Department of Clinical Pharmacology, Medicine and Therapeutic, Al- Mustansiriya 
      University, Baghdad, Iraq.
FAU - Al-Gareeb, Ali Ismail
AU  - Al-Gareeb AI
AD  - Department of Clinical Pharmacology, Medicine and Therapeutic, Al- Mustansiriya 
      University, Baghdad, Iraq.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - J Pak Med Assoc
JT  - JPMA. The Journal of the Pakistan Medical Association
JID - 7501162
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 104982-03-8 (Osteocalcin)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Blood Glucose
MH  - Case-Control Studies
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Drug Therapy, Combination
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - *Metformin/therapeutic use
MH  - Obesity/complications
MH  - Osteocalcin/therapeutic use
OTO - NOTNLM
OT  - Osteocalcin, Type 2 diabetes mellitus, Obesity, Metformin, Sitagliptin.
EDAT- 2022/02/08 06:00
MHDA- 2022/02/10 06:00
CRDT- 2022/02/07 17:12
PHST- 2022/02/07 17:12 [entrez]
PHST- 2022/02/08 06:00 [pubmed]
PHST- 2022/02/10 06:00 [medline]
PST - ppublish
SO  - J Pak Med Assoc. 2021 Dec;71(Suppl 8)(12):S4-S10.